Illumina Aims to Have FDA-Cleared Dx, CLIA Lab In ‘09; CEO Says Arrays Have Dx Future

The firm’s first assay will run on its digital microbead-based BeadXpress reader, but the CLIA lab will offer both sequencing and array-based services, a sign that Illumina believes these two platforms may play a larger role in its diagnostics offering in the future.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.